List of Tosymra drug patents

Tosymra is owned by Upsher Smith Labs.

Tosymra contains Sumatriptan.

Tosymra has a total of 8 drug patents out of which 0 drug patents have expired.

Tosymra was authorised for market use on 25 January, 2019.

Tosymra is available in spray;nasal dosage forms.

Tosymra can be used as acute treatment of migraine.

The generics of Tosymra are possible to be released after 19 July, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9283280 UPSHER SMITH LABS Compositions for drug administration
May, 2026

(3 years from now)

US8268791 UPSHER SMITH LABS Alkylglycoside compositions for drug administration
May, 2026

(3 years from now)

US8440631 UPSHER SMITH LABS Compositions for drug administration
May, 2026

(3 years from now)

US11337962 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US9974770 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US9610280 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US10603305 UPSHER SMITH LABS Formulations comprising triptan compounds
Jun, 2030

(7 years from now)

US9211282 UPSHER SMITH LABS Formulations comprising triptan compounds
Jul, 2031

(8 years from now)

Drugs and Companies using SUMATRIPTAN ingredient

Market Authorisation Date: 25 January, 2019

Treatment: Acute treatment of migraine

Dosage: SPRAY;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in